APC-A*02:01/HIV-1 gag (SLYNTVATL) MHC Tetramer (CAT#: MHC-LC396)

Haque, Mohammad, et al. "Stem cell-derived viral antigen-specific T cells suppress HIV replication and PD-1 expression on CD4+ T cells." Viruses 13.5 (2021): 753. https://doi.org/10.3390/v13050753

This research investigates the potential of stem cell-derived viral antigen-specific T cells to suppress HIV replication and prevent CD4+ T cell exhaustion. The study generated HIV-1 Gag epitope SL9-specific cytotoxic T lymphocytes from induced pluripotent stem cells (iPSCs) and tested their efficacy in a murine model using EcoHIV, a chimeric HIV-1 virus. The researchers demonstrated that adoptive transfer of these SL9-specific iPSC-CTLs significantly suppressed viral replication in peritoneal macrophages and spleen tissues. Importantly, the treatment reduced PD-1 expression on CD4+ T cells, indicating prevention of T cell exhaustion, and generated persistent anti-HIV memory T cells that could provide long-term protection against HIV infection.
Creative Biolabs provided the HLA-A201-HIV177-85-PE tetramer (CAT#: MHC-LC396) that was crucial for detecting and tracking the SL9-specific T cells in this study. This reagent enabled the researchers to precisely identify and analyze the HIV-specific T cell populations, allowing them to assess T cell persistence and functionality after adoptive transfer. The quality and specificity of this tetramer were essential for demonstrating the potential of iPSC-derived T cells as an immunotherapeutic approach for combating chronic HIV infection, which could eventually lead to new cellular therapy strategies combining antiretroviral treatment with immune cell-based therapies.